CNS Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1 | 2 | ||
EBITDA | -2,553 | -4,929 | -5,952 | -3,215 |
EBIT | -2,584 | -4,930 | -5,953 | -3,216 |
Net Income | -2,588 | -4,937 | -5,955 | -3,218 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -3,543 | -4,654 | -3,069 | -2,174 |
Cash | 19,985 | 2,950 | 7,201 | 9,864 |
Basic Shares | 6,838 | 676 | 443 | 558 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -3 | -4 | -11 | |
EBITDA | -15,831 | -14,838 | -18,833 | -15,255 |
EBIT | -15,835 | -14,841 | -18,837 | -15,267 |
Net Income | -15,850 | -14,857 | -18,851 | -15,274 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -13,829 | -17,117 | -14,143 | -10,562 |
Cash | 7,201 | 6,461 | 548 | 10,055 |
Basic Shares | 443 | 31 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.38 |
2026-03-31 | -$7.30 |
2025-12-31 | -$10.15 |
2025-09-30 | -$5.76 |